Full-Time
Posted on 8/20/2026
Implantable brain-responsive neuromodulation for epilepsy
$156k/yr
Raleigh, NC, USA
Hybrid
Approximately 80% travel to customer clinics, hospitals, and offsite meetings is required.
Bachelor's
See people who can refer or advise you
NeuroPace develops the RNS System, a brain-responsive neuromodulation device for treating refractory epilepsy. The implanted system monitors brain activity and delivers targeted electrical stimulation when abnormal patterns are detected to reduce seizures. Clinicians receive data and analysis to guide therapy, and the company sells devices with ongoing support. The goal is to broaden adoption, expand to other neurological disorders, and grow revenue while improving seizure control and quality of life for patients.
Company Size
201-500
Company Stage
IPO
Headquarters
Mountain View, California
Founded
1999
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Health Savings Account/Flexible Spending Account
Paid Vacation
Paid Holidays
Remote Work Options
529 plan
Employee Stock Purchase Plan
Company Equity
Training Programs
Wellness Program
Commuter Benefits
NeuroPace Inc reported total revenue of $22.8 million in Q2 2026, up 17% from $19.5 million the previous year. RNS system revenue reached $22.5 million, showing 21.3% growth compared to Q2 2025. The company's adjusted gross margin was 83.4%, slightly down from 84% in the prior year period. Adjusted loss from operations improved to $2.8 million from $5 million in Q2 2025, whilst adjusted net loss narrowed to $3.9 million from $6.8 million. NeuroPace held £51.9 million in cash equivalents, short-term investments and restricted cash as of 30 June 2026. The company raised its full-year 2026 total revenue guidance to $99.5 million to $101.5 million and improved its adjusted EBITDA loss guidance to between $7.5 million and $8.5 million.
NeuroPace reported 21% core RNS System revenue growth in Q2 2026, driven by expanding its prescriber base and increased utilisation at Level 4 epilepsy centres. The company reached record levels of active prescribers and patient pipelines. The firm raised its full-year revenue guidance to $99.5 million–$101.5 million, primarily reflecting better visibility into service revenue. NeuroPace is addressing the FDA's "not approvable" letter for its IGE supplement through additional clinical data, including 24-month results showing a 100% median reduction in GTC seizures among evaluable patients. The company launched ECoG Assistant, an AI-based tool designed to improve clinician workflow. Management plans to submit its remote care platform to the FDA by year-end 2026 and targets cash flow breakeven by end of 2027.
NeuroPace (NPCE) expected to release earnings on Tuesday. August 4, 2026 Key points. * NeuroPace is expected to report Q2 2026 results after the market closes on August 11. Analysts forecast a loss of $0.19 per share and revenue of approximately $22.6 million. * In the previous quarter, NeuroPace reported a smaller-than-expected loss of $0.13 per share and revenue of $22.0 million, exceeding consensus estimates. * Shares recently traded at $13.78, below their 50-day and 200-day moving averages. Analysts maintain a consensus "Moderate Buy" rating with an average price target of $19.29, while institutional investors own 78.83% of the stock. * Five stocks to consider instead of NeuroPace. NeuroPace (NASDAQ:NPCE - Get Free Report) is projected to post its Q2 2026 results after the market closes on Tuesday, August 11th. Analysts expect the company to post earnings of ($0.19) per share and revenue of $22.6130 million for the quarter. Parties may visit the the company's upcoming Q2 2026 earning results page for the latest details on the call scheduled for Tuesday, August 11, 2026 at 8:00 AM ET. NeuroPace (NASDAQ:NPCE - Get Free Report) last posted its earnings results on Tuesday, May 12th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.06. NeuroPace had a negative net margin of 21.67% and a negative return on equity of 108.20%. The firm had revenue of $22.00 million during the quarter, compared to the consensus estimate of $21.65 million. NeuroPace stock performance. Shares of NASDAQ:NPCE traded up $0.28 during midday trading on Tuesday, reaching $13.78. 60,627 shares of the company traded hands, compared to its average volume of 202,962. The firm's fifty day moving average price is $15.84 and its two-hundred day moving average price is $15.51. The firm has a market capitalization of $469.86 million, a price-to-earnings ratio of -21.19 and a beta of 1.92. The company has a quick ratio of 4.35, a current ratio of 5.38 and a debt-to-equity ratio of 4.08. NeuroPace has a 12 month low of $7.56 and a 12 month high of $19.60. Institutional trading of NeuroPace. A number of institutional investors have recently modified their holdings of NPCE. Legal & General Group Plc increased its holdings in shares of NeuroPace by 86.0% in the 2nd quarter. Legal & General Group Plc now owns 2,679 shares of the company's stock worth $30,000 after acquiring an additional 1,239 shares during the period. Quarry LP boosted its holdings in NeuroPace by 94.9% during the third quarter. Quarry LP now owns 3,845 shares of the company's stock worth $40,000 after buying an additional 1,872 shares in the last quarter. Man Group plc increased its holdings in shares of NeuroPace by 9.7% in the fourth quarter. Man Group plc now owns 21,626 shares of the company's stock valued at $334,000 after buying an additional 1,920 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its stake in shares of NeuroPace by 23.0% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 14,836 shares of the company's stock worth $230,000 after acquiring an additional 2,778 shares in the last quarter. Finally, Quantbot Technologies LP acquired a new position in shares of NeuroPace in the 2nd quarter worth $35,000. 78.83% of the stock is currently owned by hedge funds and other institutional investors. Wall Street analysts forecast growth. Several equities research analysts have recently weighed in on NPCE shares. HC Wainwright reiterated a "buy" rating and set a $20.00 price target on shares of NeuroPace in a research report on Wednesday, July 29th. Guggenheim reiterated a "neutral" rating on shares of NeuroPace in a research note on Wednesday, July 29th. Mizuho initiated coverage on shares of NeuroPace in a report on Thursday, July 23rd. They issued an "outperform" rating and a $22.00 price target for the company. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of NeuroPace in a report on Wednesday, June 24th. Two equities research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $19.29. Discover more Stocks & Bonds NeuroPace company profile. NeuroPace, Inc is a medical device company based in Mountain View, California, that develops innovative neuromodulation systems for the treatment of neurological disorders. Founded in the late 1990s out of research at Stanford University, the company's mission centers on delivering closed-loop, "smart" therapies that monitor and respond to electrical activity in the brain. In 2020, NeuroPace completed its initial public offering and now trades on the NASDAQ under the ticker NPCE. The company's flagship product, the RNS(R) System, is an implantable device designed for adults with medically refractory focal epilepsy. Further reading. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider NeuroPace, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and NeuroPace wasn't on the list. While NeuroPace currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. The space race is growing fast, and you don't have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.
NeuroPace has received FDA approval for ECoG Assistant, the first AI-driven tool designed to assist epilepsy care using long-term intracranial EEG data. The feature was announced on 29 May. Built on 124,450 epileptologist-labelled records, the tool enables physicians to review trends and timing patterns across months through integrated reports and charts, improving efficiency in data review and treatment decisions. Chief Medical Officer Martha Morrell called it an "important advancement" for faster clinical insights. The company unveiled the technology at the ASSFN Annual Meeting on 30 May. NeuroPace has submitted its next-generation patient data platform for FDA review, targeting approval in the second quarter of 2026. The company develops implantable devices for treating epilepsy and neurological conditions.
NeuroPace, Inc. (NPCE) Reveals FDA Approval of ECoG Assistant(TM). Published on june 27, 2026 at 11:31 am by fatima gulzar in news. On May 29, NeuroPace, Inc. (NASDAQ:NPCE) said it received U.S. Food and Drug Administration approval for ECoG Assistant, the first "AI-driven clinician-enabled feature." It is designed to help epilepsy care using long-term intracranial EEG data. Built on 124,450 epileptologist-labeled records, the company reported that the tool has "ECoGs of Interest." It allows physicians to review trends and timing patterns across months through integrated reports and charts, improving efficiency in data review and treatment decisions. Chief Medical Officer Martha Morrell said the feature "represents an important advancement," with faster access to insights for more informed care. CEO Joel Becker said the approval shows how the firm's data advantage is moving toward "practical tools for clinicians." NeuroPace, Inc. (NASDAQ:NPCE) debuted the technology at the ASSFN Annual Meeting on May 30. It has submitted its next-generation patient data platform for FDA review, targeting approval in the second quarter of 2026. NeuroPace, Inc. (NASDAQ:NPCE) creates, produces, and markets implantable devices to treat epilepsy and neurological illnesses. It offers implantable components such as the RNS neurostimulator and depth and cortical strip leads. While we acknowledge the risk and potential of NPCE as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than NPCE and that has 10,000% upside potential, check out our report about the cheapest AI stock.